Study Evaluating MST-997 in Advanced Malignant Solid Tumors

Phase 1TerminatedNCT00277836

Wyeth is now a wholly owned subsidiary of Pfizer60 enrolled

Overview

MST-997 is a taxane analog with the potential to treat subjects with a variety of tumor types. Preclinical data demonstrated that MST-997 inhibited tumor growth when administered intravenously (IV). This phase 1 dose escalation study is designed to evaluate the safety and tolerability of if IV MST-997 formulated in Polysorbate 80 Diluent can be safely administered on a weekly basis.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Neoplasms

Interventions

MST-997DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Documented diagnosis of malignant solid tumor with measurable disease * Life expectancy of at least 12 weeks * ECOG (Eastern Cooperative Oncology Group) performance status of 0,1,or 2 Exclusion Criteria: * Recent major surgery, radiation therapy or anti-cancer treatment * History of any other prior malignancy within last 5 years

Locations (1)

Unnamed facility

Houston, Texas, United States

Outcomes

Primary Outcomes

To evaluate the safety, tolerability and MTD (maximum tolerated dose) of MST-997.

Secondary Outcomes

Preliminary pharmacokinetic information on the pharmacokinetics (during cycle 1) abd anti-tumor activity (assessed approximately every 8 weeks) of on MST-997

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.